Abstract Library

#4194 Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well-differentiated pancreatic neuroendocrine tumors

Introduction: Temozolomide (TMZ), an alkylating agent, is an effective treatment used in multiple tumor types including advanced pancreatic neuroendocrine tumors (PanNET). In glioblastomas, TMZ induces a hypermutator and hyperprogressor phenotype in a subset of patients through MMR deficiency. In advanced colon cancer, TMZ priming increases tumor mutational burden (TMB), favouring immunotherapy efficacy.

Conference:

Presenting Author: de Mestier L

Authors: de Mestier L, Cohen D, de Rycke O, Masliah Planchon J, Fleischmann Z,

Keywords: temozolomide, hypermutation, pancreatic neuroendocrine tumor,

#3569 Outcomes of Streptozotocin (STZ)-based chemotherapy (CT) in patients with advanced pancreatic neuroendocrine tumors (pNETs): Data from the Spanish Taskforce of Neuroendocrine and Endocrine Tumors (GETNE) national registry (R-GETNE)

Introduction: STZ-based CT has been used for advanced pNETs with rapid growth, high tumor load or progression to somatostatin analogues (SSA). Evidence supporting use of STZ-based CT in pNET is mainly retrospective, and there is an unmet need of prospective trials in this setting. We present data from the R-GETNE regarding the use of STZ in spanish centers.

Conference:

Presenting Author:

Authors: Esteban-Villarrubia J, Hernando J, Garcia A, Jimenez-Fonseca P, Teulé A,

Keywords: Streptozotocin, Chemotherapy, pNET, GETNE, R-GETNE,

#3406 Neoadjuvant treatment in locally advanced pancreatic neuroendocrine tumor G3

Introduction: Bordeline or locally advanced pancreatic neuroendocrine tumors are potentially resectable in selected cases. The role of neoadjuvant chemotherapy has not been established, and there are published only few small studies dealing with this issue.

Conference:

Presenting Author: Pindura M

Authors: Pindura M, Kyčina R, Palkoci B, Nosakova L, Uhrík P,

Keywords: pancreatic neuroendocrine tumor, neoadjuvant treatment, surgery, locally advanced neuroendocrine pancreatic tumor,

#3252 Streptozotocin resistant pancreatic neuroendocrine tumor cell lines as a tool to understand chemotherapy resistance in pNET

Introduction: Streptozotocin based chemotherapy is standard of care in patients with advanced pancreatic neuroendocrine tumors (pNET). Although partial remission can initially be achieved in up to 40% of patients, primary non-responders and development of secondary progression under therapy is a major clinical challenge. So far, the mechanism leading to streptozotocin resistance have not been elucidated.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Schrader J

Authors: Viol F, Amin T, Fahl M, Izbicki J, Schrader J,

Keywords: streptozotocin, pNET, MGMT,

#2887 CHOI Criteria Are More Accurate Than RECIST in Advanced Pancreatic Neuroendocrine Tumors Treated with Sunitinib: Data from the CRIPNET-GETNE1504 Study

Introduction: Comparative data suggest greater accuracy of Choi vs RECIST in some cancers such as pancreatic neuroendocrine tumors (panNET) treated with antiangiogenic agents.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Jimenez-Fonseca P, Fernandez del Valle A, Solis M, Garcia Carbonero R, Custodio A,

Keywords: CHOI, RECIST, Response, Sunitinib, Survival,